Exclusive-Kimberly-Clark readies asset sales in bid for EU nod for Kenvue deal, sources say
Kimberly-Clark (KMB) is preparing asset sales to address EU antitrust concerns regarding its $40 billion acquisition of Kenvue. The EU is expected to formally raise its concerns this week, with Kimberly-Clark facing a September 29 deadline to submit concessions or face a full investigation. The deal has already received conditional approval in Australia and South Africa.
How this was made
The 30-second read
Why it matters
The concession strategy signals progress toward EU clearance, which is critical for deal closure.
Market read
EU approval is the final hurdle for a mega‑cap consumer health merger, affecting both stocks and sector dynamics.
What to watch
Potential antitrust concerns in other jurisdictions and integration risks.
Background
Kimberly-Clark announced a $40B acquisition of Kenvue in November 2025. EU regulators are reviewing the deal for competition concerns.
Ticker impact
Kimberly-Clark is preparing EU antitrust concessions to secure approval for its $40B acquisition of Kenvue.
KMB likely to rise on approval expectations; KENV may see a premium rally.
Deal size and EU regulatory hurdle are material; first disclosure of concession strategy.
Market effects
Consolidation in consumer health and personal care sector.
EU regulatory outcome may affect other cross‑border M&A in the region.
Large $40B deal influences global consumer goods market sentiment.
Counterpoint
EU may impose stricter divestitures, delaying or derailing the transaction.
Key entities
- CompanyKimberly-Clark
US consumer products maker seeking to acquire Kenvue.
- CompanyKenvue
Owner of brands like Listerine, Aveeno, Neutrogena.
- RegulatorEuropean Commission
EU competition authority reviewing the merger.
